Multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary ...
Netherlands-based Pharming Group today released positive top-line results of data from its Phase III clinical trial ...
Multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency Data consistent with the improvements seen in the previously ...